However, even in advanced NSCLC, where various biomarkers have already been described and the analysis of EGFR and ALK mutations is clinically available, most patients are stratified for chemotherapy based on histological data only1, 20, 21, 39, 43, 44, 45, 46, 47. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.